

## Unprecedented exploration generates most comprehensive map of cancer genomes charted to date

*Pan-Cancer Project discovers causes of previously unexplained cancers, pinpoints cancer-causing events and zeroes in on mechanisms of development*

5 February 2020 **An international team has completed the most comprehensive study of whole cancer genomes to date, significantly improving our fundamental understanding of cancer and signposting new directions for its diagnosis and treatment.**

The ICGC/TCGA<sup>1</sup> Pan-Cancer Analysis of Whole Genomes Project (PCAWG), known as the Pan-Cancer Project), a collaboration involving more than 1,300 scientists and clinicians from 37 countries, analyzed more than 2,600 genomes of 38 different tumour types, creating a huge resource of primary cancer genomes. This was then the launch-point for 16 working groups studying multiple aspects of cancer's development, causation, progression and classification.

Previous studies focused on the 1 per cent of the genome that codes for proteins, analogous to mapping the coasts of the continents. The Pan-Cancer Project explored in considerably greater detail the remaining 99 per cent of the genome, including key regions that control switching genes on and off -- analogous to mapping the interiors of continents versus just their coastlines.

The Pan-Cancer Project has made available a comprehensive resource for cancer genomics research, including the raw genome sequencing data, software for cancer genome analysis, and multiple interactive websites exploring various aspects of the Pan-Cancer Project data.<sup>2</sup>

The Pan-Cancer Project extended and advanced methods for analyzing cancer genomes which included cloud computing, and by applying these methods to its large dataset, discovered new knowledge about cancer biology and confirmed important findings of previous studies. In 23 papers published today in *Nature* and its affiliated journals, the Pan-Cancer Project reports that:

- The cancer genome is finite and knowable, but enormously complicated. By combining sequencing of the whole cancer genome with a suite of analysis tools, we can characterize every genetic change found in a cancer, all the processes that have generated those mutations, and even the order of key events during a cancer's life history.
- Researchers are close to cataloguing all of the biological pathways involved in cancer and having a fuller picture of their actions in the genome. At least one causal mutation was found in virtually all of the cancers analyzed and the processes that generate mutations were found to be hugely diverse -- from changes in single DNA letters to the reorganization of whole chromosomes. Multiple novel regions of the genome controlling how genes switch on and off were identified as targets of cancer-causing mutations.

---

<sup>1</sup> ICGC - International Cancer Genome Consortium (<https://icgc.org/>); TCGA - The Cancer Genome Atlas (<https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>)

<sup>2</sup> PCAWG Portal ([dcc.icgc.org/pcawg](http://dcc.icgc.org/pcawg)); UCSC Xena ([pcawg.xenahubs.net](http://pcawg.xenahubs.net)); Expression Atlas ([www.ebi.ac.uk/gxa/home](http://www.ebi.ac.uk/gxa/home)); PCAWG-Scout ([pcawgscout.bsc.es](http://pcawgscout.bsc.es)); Chromothripsis Explorer ([compbio.med.harvard.edu/chromothripsis](http://compbio.med.harvard.edu/chromothripsis))

- Through a new method of “carbon dating,” Pan-Cancer researchers discovered that it is possible to identify mutations which occurred years, sometimes even decades, before the tumour appears. This opens, theoretically, a window of opportunity for early cancer detection.
- Tumour types can be identified accurately according to the patterns of genetic changes seen throughout the genome, potentially aiding the diagnosis of a patient’s cancer where conventional clinical tests could not identify its type. Knowledge of the exact tumour type could also help tailor treatments.

*“The findings we have shared with the world today are the culmination of an unparalleled, decade-long collaboration that explored the entire cancer genome,”* says Dr. Lincoln Stein, member of the project steering committee and Head of Adaptive Oncology at the Ontario Institute for Cancer Research (OICR). *“With the knowledge we have gained about the origins and evolution of tumours, we can develop new tools and therapies to detect cancer earlier, develop more targeted therapies and treat patients more successfully.”*

*“This work is helping to answer a long-standing medical difficulty, why two patients with what appear to be the same cancer can have very different outcomes to the same drug treatment. We show that the reasons for these different behaviours are written in the DNA. The genome of each patient’s cancer is unique, but there are a finite set of recurring patterns, so with large enough studies we can identify all these patterns to optimize diagnosis and treatment.”* said Dr. Peter Campbell, member of the Pan-Cancer Project steering committee and Head of Cancer, Ageing and Somatic Mutation at the Wellcome Sanger Institute in the UK.

*“This study provides the most complete picture to date of cancer-causing mutations in all parts of the genome. It was a massive team science effort involving researchers spanning the globe,”* said steering committee member Josh Stuart, a professor of biomolecular engineering at UC Santa Cruz. *“At UC Santa Cruz, our strengths in systems biology and RNA expression helped us connect findings in the previously unexplored noncoding genome with the pathways that lead to cancer. Like a charted map, this new work creates a reference and resource that researchers can use to interpret future data and physicians can use to guide treatment.”*

*“With the continuing drop in sequencing costs and accumulation of genomic data across increasing numbers of patients worldwide, the comprehensive analyses performed in this project will serve as a template for future work and will enable new discoveries in cancer,”* said steering committee member, Dr. Gad Getz, professor of pathology at the Massachusetts General Hospital and the Broad Institute of MIT and Harvard.

*“This huge international study was only possible due to the work and collaboration of more than a thousand researchers and clinicians across the world, and I would like to thank everyone involved,”* said steering committee member Dr. Jan Korbel from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.

*“The completion of this project represents the culmination of more than a decade of ground-breaking work in studying the cancer genome,”* said Dr. Tom Hudson, Chief Scientific Officer at AbbVie and a founder of the International Cancer Genome Consortium. *“When we launched ICGC in 2007, an initiative of this magnitude was unprecedented. I am thrilled that the scientific community has come together to produce this comprehensive study, which enhances our understanding of cancer and fosters the development of new medicines for cancer patients.”*

*“ICGC’s latest initiative called ARGO (Accelerating Research in Genomic Oncology) is about the patient, with the goal of delivering to the world 1 million patient-years of precision oncology knowledge to improve human health. This data must be shared across traditional jurisdictional boundaries to realize the full impact of precision medicine, for the benefit of all.” Andrew Biankin AO, Regius Professor of Surgery and Director of the Wolfson Wohl Cancer Research Centre at the University of Glasgow, and Executive Director, International Cancer Genome Consortium.*

*“Using the data and infrastructure created by The Cancer Genome Atlas (TCGA) as a blueprint, PCAWG has further improved our understanding of cancer and strengthened our ability to develop successful, international projects of this scale,” said Jean Claude Zenklusen, Ph.D., director of TCGA Program Office at the National Cancer Institute (NCI). “In addition to benefiting the cancer research field, this collaboration also honors the many patients who donated samples to TCGA – turning their finite gift of tissue into data that can be used infinitely,” said Carolyn Hutter, Ph.D., National Human Genome Research Institute team lead for TCGA.*

### **More information**

ICGC - International Cancer Genome Consortium (<https://icgc.org/>)

TCGA - The Cancer Genome Atlas (<https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>)

PCAWG - PanCancer Analysis of Whole Genomes (<dcc.icgc.org/pcawg>)

Expression Atlas ([www.ebi.ac.uk/gxa/home](http://www.ebi.ac.uk/gxa/home))

PCAWG-Scout ([pcawgscout.bsc.es](http://pcawgscout.bsc.es))

Chromothripsis Explorer ([compbio.med.harvard.edu/chromothripsis](http://compbio.med.harvard.edu/chromothripsis))

### **About the Ontario Institute for Cancer Research**

*OICR is a collaborative, not-for-profit research institute funded by the Government of Ontario. We conduct and enable high-impact translational cancer research to accelerate the development of discoveries for patients around the world while maximizing the economic benefit of this research for the people of Ontario. For more information visit [www.oicr.on.ca](http://www.oicr.on.ca).*

### **About the Broad Institute of MIT and Harvard**

*Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff, and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to <http://www.broadinstitute.org>.*

### **About the Massachusetts General Hospital**

*Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The [MGH Research Institute](#) conducts the largest hospital-based research program in the nation, with an annual research budget of more than \$1 billion and comprises more than 8,500 researchers working across more than 30 institutes, centers and*

departments. In August 2019 the MGH was once again named #2 in the nation by U.S. News & World Report in its list of "America's Best Hospitals."

### **About the Wellcome Sanger Institute**

The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; we share our data, results, tools and technologies across the world to advance science. Our findings are used to improve health and to understand life on Earth. Find out more at [www.sanger.ac.uk](http://www.sanger.ac.uk) or follow us on Twitter, Facebook, LinkedIn and on our Blog.

### **About the European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI)**

EMBL is Europe's flagship laboratory for the life sciences. We are an intergovernmental organisation established in 1974 and are supported by over 20 member states. EMBL performs fundamental research in molecular biology, studying the story of life. We offer services to the scientific community; train the next generation of scientists and strive to integrate the life sciences across Europe.

We are international, innovative and interdisciplinary. We are more than 1600 people, from over 80 countries, operating across six sites in Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Cambridge (UK), Rome (Italy), and Barcelona (Spain). Our scientists work in independent groups and conduct research and offer services in all areas of molecular biology. Our research drives the development of new technology and methods in the life sciences. We work to transfer this knowledge for the benefit of society. For more information, visit [www.embl.de](http://www.embl.de).

### **About the University of California, Santa Cruz**

UC Santa Cruz is a public university combining the intimacy of a small, liberal arts college with the depth and rigor of a major research university. The UC Santa Cruz Genomics Institute creates advanced technologies and open-source genomics platforms to unravel evolutionary patterns, molecular processes, and the underpinnings of disease. The Genomics Institute's platforms, technologies and scientists unite global communities to create and deploy data-driven, life-saving treatments and innovative environmental and conservation efforts. For more information, visit [www.ucsc.edu](http://www.ucsc.edu) and [genomics.ucsc.edu](http://genomics.ucsc.edu).

### **About The National Cancer Institute and The National Human Genome Research Institute, National Institutes of Health**

The National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), jointly manage The Cancer Genome Atlas (TCGA), a landmark cancer genomics program. For more information about TCGA, visit <https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>

**NCI** leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information, visit the NCI website at <https://www.cancer.gov> or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

**NHGRI** is one of the 27 institutes and centers at the National Institutes of Health. The NHGRI Extramural Research Program supports grants for research and training and career development at sites nationwide. Additional information about NHGRI can be found at <http://www.genome.gov>

### **About the University of Glasgow**

As one of the top 100 of the world's universities, we deliver world-class, world-changing research and education with impact. We are a member of the prestigious Russell Group of leading UK Universities with annual research income of more than £179m. We're currently investing £1 billion in our estate to create spaces and opportunities that will allow us to remain at the forefront of change excellence and innovation. Information about ICGC-ARGO can be found at [www.icgc-argo.org](http://www.icgc-argo.org).

### **Media contacts**

Hal Costie  
Ontario Institute for Cancer Research  
647-260-7921  
[hal.costie@oicr.on.ca](mailto:hal.costie@oicr.on.ca)

Mathias Jager  
EMBL Heidelberg, Germany  
49-6221-387-8726  
[mathias.jaeger@embl.de](mailto:mathias.jaeger@embl.de)

Oana Stroe  
EMBL-EBI, U.K.  
44-1223-494-369  
[stroe@ebi.ac.uk](mailto:stroe@ebi.ac.uk)

Samantha Wynne  
Wellcome Sanger Institute, UK  
44-1223-492368  
[press.office@sanger.ac.uk](mailto:press.office@sanger.ac.uk)

David Cameron  
Broad Institute of MIT and Harvard  
617-714-7184  
[dcameron@broadinstitute.org](mailto:dcameron@broadinstitute.org)

Tim Stephens  
University of California, Santa Cruz  
831-459-4352  
[stephens@ucsc.edu](mailto:stephens@ucsc.edu)

*The Cancer Genome Atlas*  
*National Cancer Institute, National Institutes of Health*  
240-760-6600  
240-276-7214  
301-605-0679  
[NCIPressOfficers@nih.gov](mailto:NCIPressOfficers@nih.gov)

*Ali Howard OR Elizabeth McMeekin*  
*ICGC-ARGO*  
*University of Glasgow*  
+44 (0)141 330 3535  
[ali.howard@glasgow.ac.uk](mailto:ali.howard@glasgow.ac.uk) OR [Elizabeth.mcmeekin@glasgow.ac.uk](mailto:Elizabeth.mcmeekin@glasgow.ac.uk)